Tvedskov Tove Filtenborg
Department of Breast Surgery, Gentofte Hospital, Hellerup, Denmark.
Gland Surg. 2023 Dec 26;12(12):1774-1785. doi: 10.21037/gs-23-362. Epub 2023 Dec 22.
With the improved survival for breast cancer there is now an increased focus on quality of life after treatment. Axillary surgery is known to be associated with significant risk of arm morbidity feared by the patients, and several studies have shown de-escalation is possible in different settings. In this review, an overview will be given on new techniques and procedures for de-escalation of axillary surgery in breast cancer patients and the subsequent implications for adjuvant systemic treatment.
This study is a narrative review. PubMed was searched for relevant publications in English published between January 2018-June 2023. Only publications with major impact on clinical practice have been included with main emphasis on meta-analysis. In addition, Clinicaltrial.gov has been searched for on-going studies.
New tracer techniques are described as well as the on-going reduction in axillary lymph node dissection (ALND) at primary surgery even in node positive patients, and the axillary staging possibilities after down-staging of the axilla by neoadjuvant treatment. Finally axillary staging at local recurrence and in case of ductal carcinoma in situ is described.
ALND is no longer routinely recommended in many node positive patients and further de-escalation is investigated. The lack of knowledge on precise axillary status will require cooperating studies between oncologists and breast surgeons in order to avoid escalation of systemic treatment due to the lack of applicability of trial eligibility criteria. Furthermore, investigations on the use of axillary imaging for staging are needed.
随着乳腺癌患者生存率的提高,目前对治疗后生活质量的关注日益增加。已知腋窝手术会给患者带来手臂发病的重大风险,并且多项研究表明在不同情况下可以进行降阶梯治疗。在本综述中,将概述乳腺癌患者腋窝手术降阶梯的新技术和程序,以及对辅助全身治疗的后续影响。
本研究为叙述性综述。在PubMed上搜索了2018年1月至2023年6月期间以英文发表的相关出版物。仅纳入了对临床实践有重大影响的出版物,主要侧重于荟萃分析。此外,还在Clinicaltrial.gov上搜索了正在进行的研究。
描述了新的示踪技术,以及即使在淋巴结阳性患者的初次手术中腋窝淋巴结清扫(ALND)的持续减少,以及新辅助治疗使腋窝降阶梯后的腋窝分期可能性。最后描述了局部复发时以及原位导管癌情况下的腋窝分期。
在许多淋巴结阳性患者中,不再常规推荐ALND,并且正在研究进一步的降阶梯治疗。由于缺乏试验入选标准的适用性,对精确腋窝状态的知识缺乏将需要肿瘤学家和乳腺外科医生之间的合作研究,以避免全身治疗的升级。此外,需要对腋窝成像用于分期的应用进行研究。